Abstract: The present invention provides a disease model animal for tauopathies which reproduces the expression pattern of tau protein isoforms of adult human brain, that is, approximately equal amounts of 3R type tau and 4R type tau being expressed in the adult brain. The method for producing the disease model animal for tauopathies of the present invention comprises the steps of: preparing a tau seeds; and injecting the tau seeds in the brain of an animal carrying a mutation in the tau gene which fails to express the tenth exon. The animal carrying a mutation in the tau gene which fails to express the tenth exon may be produced by using any of the genome editing, gene targeting or base editing technologies.

Abstract: The invention provides an atrial fibrillation risk prediction system based on heartbeat rhythm signals. A heartbeat rhythm signal preprocessing module obtains heartbeat interval sequence data by calculating the time interval of two adjacent heartbeats. During sample labeling, a positive sample is from heartbeat interval data during the sinus heart rate period of a case with high AF risk, and a negative sample is from heartbeat interval data of a case with low AF risk; and an atrial fibrillation risk prediction model is trained with positive and negative samples and is used to test heartbeat interval data, an AF risk curve between the proportion of positive samples and output probability thresholds is obtained according to the output probabilities of testing samples, the area under the AF risk curve is calculated as the atrial fibrillation risk value, and the value can reflect the atrial fibrillation risk.

Abstract: The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc. The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.

Abstract: A novel device, method and kit for reconstitution of a solid or semi-solid pharmaceutical composition by a negative pressure differential includes (i) a first adapter with a first connector, a first peripheral wall wherein the first adapter is coupled to the first vial by means of a first connector; (ii) a second adapter with a second connector, a second peripheral wall wherein the second adapter is coupled to the second vial by means of a second connector; (iii) a transfer port wherein the transfer port includes a first end ending in first adapter to gain access to first vial and a second end ending in second adapter to gain access to second vial; wherein the first adapters and the second adapter are joined together in vertical direction by means of horizontal wall; wherein the adapter connected to the vials by means of the ends.

Abstract: The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques. An antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS is described.

Abstract: Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.

Abstract: A novel therapeutic agent effective for the treatment of intellectual disability or autism is disclosed. The therapeutic agent for intellectual disability or autism contains, as an active component(s), at least one selected from the group consisting of tipifarnib and lonafarnib. Examples of the intellectual disability include memory impairment. Examples of the memory impairment include memory impairment caused by abnormality of the Tsc1 gene and/or Tsc2 gene, and epilepsy-induced memory impairment. Also provided is a method of treating intellectual disability or autism, comprising administering an effective amount of at least one selected from the group consisting of tipifarnib and lonafarnib to a patient with intellectual disability or autism.

Abstract: Present invention provide a system and a method for recording, evaluating, screening and monitoring life style associated Non-communicable diseases related data of a subject via an Integrated Medical Device (IMD) in real time, and sharing the same on a server, either local or cloud based, for fast, active sharing of data by remote users anytime anywhere.

Abstract: An electrode for electroporation comprising a plurality of electrode needles, wherein first polarity electrode needles, an electrode needle holding portion, and a syringe holding portion are provided; two or more first polarity electrode needles project from a bottom surface of a lower structural body of an outer frame support of the electrode needle holding portion toward an electroporation target side; the bottom surface of the lower structural body of the outer frame support is provided with a hole for syringe needle insertion and removal communicating with a syringe holding portion side; the syringe holding portion is provided on a side opposite to the electroporation target side of the electrode needle holding portion; and the syringe holding portion has a path for syringe needle insertion and removal, at least a portion of the path for syringe needle insertion and removal being provided with an electro-conductive portion for a second polarity.

Abstract: Provided is an invention that is based on the novel function of a transcription factor RP58 in cells of the central nervous system. The present invention relates to: a transgenic non-human animal capable of increasing or decreasing the expression of the transcription factor RP58 in cells of the central nervous system of a non-human animal in the nascent stage and/or during and after the developmental stage; and a pharmaceutical composition for use in the treatment or prevention of brain dysfunction, or behavioral disorder, or a disease related thereto, wherein the pharmaceutical composition comprises a transcription factor RP58 protein, or a gene encoding the transcription factor RP58; etc.

Abstract: The present invention relates to a method for estimating lung morphometry based on aerosol deposition characteristics using an imaging means such as a gamma camera to scan the lungs. An adaptive image threshold technique is used to determine the ratio of deposition in central to peripheral region of the lung (C/P ratio). The morphometric parameters such as length and diameter of distal lung airways (P8 and P9 respectively) and mean alveolar diameter (dalv) are determined from aerosol retention data and clearance data.

Abstract: The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.

Abstract: In one aspect of the invention, the present invention discloses and claims a recombinant transforming growth factor alpha (TGF ?) consisting of Sequence ID No.: 1, craving out from the whole TGF ?, and cloned for the wound healing applications. Further it discloses primers for amplifying TGF ? consisting of Sequence ID Nos.: 2 and 3, wherein sequence ID No.: 2 is forward primer, and the sequence ID No.: 3 is reserve primer for TGF ?. It further discloses a process of preparation of a vector comprising essentially of Sequence ID No.: 1, said process comprising the steps of multiplying the desired gene fragment through PCR using primers of Sequence ID No.: 2 and 3. Further, a pharmaceutical composition comprising essentially of Sequence ID No.: 1, along with additives, fillers and addendums is disclosed. Finally, it discloses a method of wound healing using the recombinant TGF ? comprising application of a pharmaceutical composition.

Abstract: Provided is a host cell for stably propagating a virulent hand, foot and mouth disease virus, the host cell expressing no heparan sulfate and overexpressing primate scavenger receptor class B member 2 (SCARB2). Also provided is a method for screening for an anti-hand, foot and mouth disease virus vaccine or an anti-hand, foot and mouth disease virus drug using a stably cultured virulent hand, foot and mouth disease virus.

Abstract: The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.

Abstract: The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques. The present invention provides an antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS.

Abstract: A 3D bioprintable ink formulation capable of multidimensional printing comprises gelatin modified by an essential amino acid arginine, oxidized alginate and a catalyst.

Abstract: The invention relates to radiopaque liquid embolic composition comprising tetra iodo compound, 4,4-bis (4-hydroxy-3,5 diiodo phenyl) valeric acid (IBHV) of Formula I, covalently linked to ethylene vinyl alcohol copolymer (EVOH) and dissolved in a water miscible organic liquid.

Abstract: A flow diverter device is used to redirect the blood flow inside the cerebral blood vessels and for the reduction of blood flow to the aneurysm, hence preventing the chance of aneurysm rupture as well as promoting the healing of the aneurysm. The novel design of the device, using a set of thicker wires, provides high kink resistance and radial strength. Two patterns of inter-braiding the thicker set of wires with the finer braid are disclosed, one having a checker-board and the other a ring structure. Both patterns are highly kink resistant with the checker-board design providing minimal loss in flexibility, whereas the ring design provides greater radial strength. The device could be made of super elastic materials like Nitinol wires with the thicker set being radio opaque. The device is highly kink resistant and sufficiently flexible for use in vasculature with complex bends.

Abstract: The present invention relates to a device (D) for occluding atrial septal defect. Non-woven wires are introduced in one or more stages, with each stage interspaced with one or more braids and braided together with the wires from the woven centre and earlier stages to form the device (D). The transcatheter device (D) has two discs (101, 102) one a hub-less disc incorporating a woven central section on the left atrial side and the other disc on the right atrial side with a connecting neck (110) braided from wires. The device (D) has thrombogenic material in either discs (101, 102). A ridge (108) is configured on the periphery of either the left atrial disc or right atrial disc or both discs to improve structural stability of the device and provides enhanced elapsing force onto the septum reducing chances of migration.